Ester prodrugs are commonly used to increase the intestinal absorption of drugs with permeabilitylimited absorption. The high functional activity of este rases in blood and liver allows a rapid bio acti vation of the prodrug after reaching the sys temic circulation. However, the increased efficiency of prodrugs to pass the intestinal barrier may be decreased by its rapid esterase-mediated hydrolysis at the level of the intestinal mucosa, offsetting the diffusion of the lipophilic, intact esters across the epithelial monolayer. This phenomenon primarily occurs at the level of the mucosa of small intestine, due to its high esterase activity. Kratak sadr`aj: Inhibitori reverzne transkriptaze su agensi koji se naj~e{}e prepisuju za infekcije HIV-om. Ova publikacija predstavlja validirani, veoma senzitivni i se lektivni izokratski HPLC metod za kvantitativno odre|i vanje te nofovir-dizoproksil-fumarata i njegovog metabolita teno fovira. Detekcija je obavljena na UV detektoru. Predstavlje na je linearnost za kalibracionu krivu u opsegu koncentra cije 80-204000 ng/mL za tenofovir-dizoproksil-fumarat (TENDF) i 10-2560 ng/mL za tenofovir (TEN). Preciznost i ta~nost predlo`enih metoda izme|u dana i tokom dana karakteri{u re lativna standardna devijacija (R.S.D.) i pro cen tualna de vijacija: obe su manje od 4% za sve analite. Limit za de tekciju bio je 33,46 ng/mL za TENDF i 2,10 ng/mL za TEN. Summary: Reverse transcriptase inhibitors are the most frequently prescribed agents for HIV infections. This publication presents a validated, highly sensitive and selective isocratic HPLC method for the quantitative determination of tenofovir disoproxil fumarate and its metabolite tenofovir. Detection was performed on a UV detector. The linearity for the calibration curve in the concentration range of 80-20400 ng/mL for tenofovir disoproxil fumarate (TENDF) and 10-2560 ng/mL for tenofovir (TEN) is presented. Inter-and intra-day precision and accuracy of the proposed method were characterised by relative standard deviation (R.S.D.) and percentage deviation, respectively: with both lower than 4% for all analytes. The limit of detection was 33.46 ng/mL for TENDF and 2.10 ng/mL for TEN.
Summary: Reverse transcriptase inhibitors are the most frequently prescribed agents for HIV infections. This publication presents a validated, highly sensitive and selective isocratic HPLC method for the quantitative determination of tenofovir disoproxil fumarate and its metabolite tenofovir. Detection was performed on a UV detector. The linearity for the calibration curve in the concentration range of 80-20400 ng/mL for tenofovir disoproxil fumarate (TENDF) and 10-2560 ng/mL for tenofovir (TEN) is presented. Inter-and intra-day precision and accuracy of the proposed method were characterised by relative standard deviation (R.S.D.) and percentage deviation, respectively: with both lower than 4% for all analytes. The limit of detection was 33.46 ng/mL for TENDF and 2.10 ng/mL for TEN.
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• C 4 H 4 O 4 and a molecular weight of 635.52. Tenofovir (TEN) (Figure 1 ) has a strong activity against human immunodeficiency virus infection in humans (1) . However, it is characterized by a permeability-limited oral absorption due to its hydrophilic nature (2) . In the prodrug, the two negative charges of TEN are masked by isopro pyloxycarbonyloxymethyl moieties, which increase the lipo philicity of the compound and thus its permeation across membranes. Based on its favourable pharmacokinetic profile compared with other ester prodrugs, TENDF was selected as an orally active form of tenofovir (3) . It was shown that the degradation of TENDF to its (mono) ester equivalent (mediated by carboxylesterases) and further to TEN (probably mediated by phosphodiesterases) at the level of the intestinal mucosa may be an important barrier limiting the transepithelial transport of TENDF (4) . Following oral administration of a single dose of 300 mg to HIV-infected patients in the fasted state, maximum serum concentrations (Cmax) of TEN are achieved in 1.0±0.4 hours. Cmax and AUC values are 296±90 ng/mL and 2287±685 ng × h/mL, respecti vely. The oral bioavailability of TENDF in fasted patients is approximately 25%. TEN is eliminated by a combination of glomerular filtration and active tubular secretion. TENDF requires initial diester hydrolysis (by non-specific esterases in blood and tissues) for conversion to TEN and subsequent phosphorylations by cellular enzymes to form TEN diphosphate, an obligate chain terminator. TEN diphosphate inhibits the activity of HIV reverse transcriptase and HIV polymerase by competing with the natural substrate deoxyadenosine 5'-triphosphate and, after incorporation into DNA, by DNA chain termination. TEN diphosphate is a weak inhibitor of mammalian DNA polymerases a, b, and mito chondrial DNA polymerase g. Some metabolic side effects associated with TEN have included hyperglycemia, increased urine glucose, fasting triglycerides, fasting cholesterol, creatine kinase, serum amylase, alkaline phosphatase, pancreatic amylase, and serum lipase, altered serum glucose, weight loss, and lactic acidosis. In such cases the health care systems also emphasize the identification and quantitation of the metabolites for comprehensive understanding of biological safety of individual metabolites; thus, revealing the need and scope of bioanalytical research in metabolite and toxicity profiling of drugs. Availability of protocols for qualitative and quantitative characterization of all metabolites will have many applications for therapeutic drug monitoring, bioequ ivalence, toxicological and all related studies. Iden tification of metabolites may be done by a variety of chroma tographic and spectroscopic techniques, either alone or in combination with other techniques. Rapid and effective ways for the determination of drugs and me tabolite in biological fluids are desirable. Conven tio nal liquid chromatography has been exploited widely in the field of metabolite profiling. Metabolite pro filing has been established as a multiparallel strategy for relative quantification of a mixture of compounds or compound classes using chromatography and uni versal detection techno logies.
Literature survey reveals that a simple reverse pha se high performance liquid chromatographic met h od for the determination of TENDF in pharma ceu tical formulations and human plasma samples is repor ted (5) (6) . In this paper we describe a rapid, se lec tive and sensitive HPLC method for simultaneous determination of TENDF and TEN in plasma. The aim of the current study was to quantitate TEN in the presence of TENDF and develop a validated high performance liquid chromatography (HPLC) assay method for the determination of TEN and TENDF from plasma. The method validation was done according to USFDA guidelines (7).
Materials and Methods

Materials
TENDF was supplied as gift sample by Cipla ltd. (Mumbai, Maharashtra, India) and used without further purification. Indapamide (IND) was supplied as gift sample by Glenmark Pharmaceutical ltd. (Goa, India). Potassium hydroxide and hydrochloric acid (both AR grade) were purchased from Loba Chemie Ltd. Chloroform was procured from S.D. Fine Chem Ltd. Methanol (HPLC grade) was purchased from Merck ltd. Double distilled water was obtained from a water distillation unit.
Instrumentation
The HPLC system used was a computer based Jasco series instrument comprising a pump PU-2080 and a UV detector UV-2070. Manual injections were carried out using a Rheodine injector with a fixed 20 μL external loop. The chromatographic sepa rations were performed on a HIQ sil C18 ODS column (250 mm length×4.6 mm internal diameter and 5 mm particle size), operating at ambient tem perature, using a mobile phase consisting of methanol:water (70:30v/v), at a flow rate of 1.0 mL/min, and detection was performed at 260 nm using a UV detector. HPLC instrument was controlled by software Borwin. The mobile phase was filtered through a 45 mm nylon membrane filter. A Shimadzu AY 120 analytical balance 
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was used for weighing. A PCi ultrasonicator was used for sonication. The calibrated glasswares were used throughout the experiment. The mobile phase was used for dilutions of de gradation samples throughout the analysis. The cha racterization was done by using FTIR: KBr (cm -1 ), 4100 JASCO and NMR: DMSO-d6 (d); 400 MHz Varian NMR.
Synthesis and characterization of TEN
TEN was synthesized at laboratory scale, and obta ined in good yield. 1 gram of TENDF was weig h ed accurately, to this 10 mL of 0.1 mol/L KOH solution was added and kept at 50 °C for three hours. The reacting solution was cooled at room tempe ra ture; to this solution 10 mL of 0.1 mol/L HCl was added. The resulted solution was extracted with 50 mL x 3 times with chloroform. Aqueous layer was evaporated on water bath to get solid TEN. The solid was recrystalized from chloroform (yield 58.30%). After drying it was characterized by IR and NMR.
Preparation of standard solutions
The stock standard solutions of TENDF and TEN were prepared by dissolving standard in mobile phase. The stock standard solutions were then diluted with mobile phase to achieve standard working solutions at concentrations 10, 20, 40, 80, 160, 320, 640, 1280 and 2560 ng/mL for both TENDF and TEN.
Stock internal standard solution was prepared by accurately weighing Indapamide (IND) which was then dissolved in mobile phase. Working internal standard was prepared by accurate dilution of the stock internal standard with mobile phase to a final concentration of 1 mg/mL. Stock internal standard was stored at 40 °C and confirmed to be stable for 5 days.
Preparation of plasma samples
To the 10 mL of blood sample 2 mL of 0.1 mol/L acetic acid was added. RBCs allow settling down. Sample was centrifuged at 5000 r.p.m. for 35 min. The supernatant was collected as plasma. The TENDF and TEN were weighed separately and dissol ved together in mobile phase in the same volumetric flask, to this solution two mL of plasma was added. Obtained solution was filtered through a syringe filter the size of 45 mm and final volume was adjusted to 100 mL with mobile phase to get stock solutions containing 100 mg/mL each of TEN and TENDF. The stock stan dard solutions were then diluted with 
Procedure for plotting calibration curve
The above nine mixed standard solutions were used for calibration curve for both the TENDF and TEN. Calibration curves were plotted by response factors against the concentrations of TENDF and TEN separately. The slope, intercept and correlation coefficient values for calibration curves were obtained for both TENDF and TEN. The overlain chromatograms are shown in Figure 2 .
Results
The metabolite (TEN) was synthesized and characterised by IR and NMR. The separation was achi ev ed with good chromatographic results. The reten tion times of TENDF and TEN are listed in Table I slope, intercept and correlation coeffi cient are summarized in Table II . The results of the recovery are summarized in Table III . The intra-and inter-day assay results (summarised in Table IV and Table V) show acceptable precision and accuracy for the proposed method. All results of stability tests pre sented in Table  VI and Table VII show good stability of TENDF and TEN concentration over all steps of determination; therefore the method is proved to be applicable for routine analyses. The system suitability parameters are shown in Table VIII .
Discussion
Characterization of TEN
The solid was recrystalized from chloroform (yield 58.30%). 
Performance of liquid chromatography
Several analytical columns (C 8 and C 18 ) were tested to obtain maximal response of TENDF and TEN and reasonable time of analysis. Symmetrical peak shapes of TENDF and TEN and IND could not be obtained easily with the C8 stationary phase. The C18 column (250 nm length x 4.6 internal diameter and 5 mm particle size) was eventually selected for assay because it exhibited excellent peak shape and it had highest response of TENDF and TEN with an acceptable run time.
The selection of mobile phase components was also a critical factor. Finally, two-component mobile phase containing methanol and water was used with satisfying results.
Validation of the TENDF and TEN assay
Specificity and selectivity. Plasma samples were tested for presence of endogenous components, which might interfere with TENDF and TEN or IND.
The plasma samples were pretreated according to the sample preparation procedure, apart from addi tion of internal standard solution. Chromato grams of blank plasma and plasma spiked with TENDF and TEN and IND were compared to show the specificity and selectivity of proposed procedure. No endoge nous components interfering with analytes and internal standard were found in the chro ma tograms of blank plasma samples.
Recovery studies. Accuracy of analysis was deter mined by performing recovery studies by spiking different concentrations of pure drug in the preanalysed samples within the analytical concentration range of the proposed method. The added quantities of the individual TENDF and TEN were estimated by the above method.
Limit of detection and quantitation. The limit of detection (LOD) was estimated as the amount of TENDF and TEN. The LOD was calculated by considering LOD=3.3s/s, where s= slope of cali bration curve and s= standard deviation of blank response. The limit of detection was calculated to be 2.10 ng/mL for TEN and 33.46 ng/mL for TENDF, respectively. The lower limit of quantitation (LLOQ) defined as the lowest concentration analysed with acceptable accuracy and precision was 10 ng/ml for TEN and 80 ng/mL for TENDF, respectively.
Linearity, accuracy and precision. The nine point calibration curve obtained by linear regression showed good linearity over the concentration range 10-2560 ng/mL for TEN and 80-20480 ng/mL for TENDF, respectively. Inter-and intra-day assays were performed to evaluate precision and accuracy. Each assay batch consisted of blank, blank with internal standard, nine calibration standards and plasma samples of the same concentration. Intra-day precision and accuracy were assessed by the analysis of four plasma samples in nine series. Inter-day precision and accuracy were determined by analysing nine series of four plasma samples in four runs within four days.
Stability. Freeze-thaw stability was determined as percent recovery. The test was carried out over four days in four runs. It was concluded that four cycles of freeze-thaw could be carried out with no loss of TENDF and TEN. The long-term stability test was performed in four runs over three months. The percent recovery was determined. The obtained data showed no loss of analytes.
Room temperature stability was assessed by analyte determination. The samples were left at room temperature for various lengths of time (0, 15, 30, 60 and 120 min) before sample processing. No significant difference was found in TENDF or TEN concentrations. All plasma samples for stability evaluation were prepared as described in the above section. To guarantee the reliability of the method, measured concentrations should not differ more.
Conclusion
The synthesis of TEN from TENDF was achieved in good yields, the synthesized metabolite was charac terised by IR and NMR spectroscopy. A method for the simultaneous determination of TENDf and its metabolite (TEN) in plasma was proposed and validated. No interference from endogenous plasma components or other sources was found. TENDF, TEN and internal standard were well separated and their peaks were narrow and symmetric. The assay showed good precision and accuracy. The analytical method presented here has proved to be useful for the simultaneous estimation of TEN with TENDF.
